SML3605
Selexipag
≥98% (HPLC)
Synonym(s):
2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide, ACT-293987, NS-304
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C26H32N4O4S
CAS Number:
Molecular Weight:
496.62
UNSPSC Code:
51111800
NACRES:
NA.21
MDL number:
Product Name
Selexipag, ≥98% (HPLC)
InChI key
QXWZQTURMXZVHJ-UHFFFAOYSA-N
SMILES string
CC(C)N(CCCCOCC(NS(C)(=O)=O)=O)C1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)N=C1
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Related Categories
Biochem/physiol Actions
Selexipag is a potent, highly selective and orally available nonprostanoid agonist for the PGI2 receptor (IP receptor). Selexipag is readily hydrolyzed to the active metabolite ACT-333679 (MRE-269), which is also a potent and selective agonist at IP receptors. In contrast to the prostacyclin analogs iloprost and beraprost, selexipag and metabolite ACT-333679 does not contract gastric fundus up to mM concentrations.
Potent, highly selective and orally available agonist for the PGI2 receptor (IP receptor); nonprostanoid IP receptor agonist
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug
Journal of Pharmacology and Experimental Therapeutics, 322, 1181-1188 (2007)
A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery
Journal of Pharmacology and Experimental Therapeutics, 326(3), 691-699 (2008)
Keith Morrison et al.
The Journal of pharmacology and experimental therapeutics, 335(1), 249-255 (2010-07-28)
Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide] is an orally available prostacyclin (PGI(2)) receptor (IP receptor) agonist that is chemically distinct from PGI(2) and is in clinical development for the treatment of pulmonary arterial hypertension. Selexipag is highly selective for the human IP receptor in
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service